PURPOSE: We report the results of a phase II study to determine the reproducibility of a submandibular salivary gland transfer (SGT) surgical technique for prevention of radiation (XRT)-induced xerostomia in a multi-institutional setting and to assess severity of xerostomia. METHODS AND MATERIALS: Eligible patients had surgery for primary, neck dissection, and SGT, followed by XRT, during which the transferred salivary gland was shielded. Intensity modulated radiation therapy, amifostine, and pilocarpine were not allowed, but postoperative chemotherapy was allowed. Each operation was reviewed by 2 reviewers and radiation by 1 reviewer. If 13 or more (of 43) were "not per protocol," then the technique would be considered not reproducible as per study design. The secondary endpoint was the rate of acute xerostomia, grade 2 or higher, and a rate of ≤ 51% was acceptable. RESULTS: Forty-four of the total 49 patients were analyzable: male (81.8%), oropharynx (63.6%), stage IV (61.4%), median age 56.5 years. SGT was "per protocol" or within acceptable variation in 34 patients (77.3%) and XRT in 79.5%. Nine patients (20.9%) developed grade 2 acute xerostomia; 2 had grade 0-1 xerostomia (4.7%) but started on amifostine/pilocarpine. Treatment for these 11 patients (25.6%) was considered a failure for the xerostomia endpoint. Thirteen patients died; median follow-up for 31 surviving patients was 2.9 years. Two-year overall and disease-free survival rates were 76.4% and 71.7%, respectively. CONCLUSIONS: The technique of submandibular SGT is reproducible in a multicenter setting. Seventy-four percent of patients were prevented from XRT-induced acute xerostomia.
PURPOSE: We report the results of a phase II study to determine the reproducibility of a submandibular salivary gland transfer (SGT) surgical technique for prevention of radiation (XRT)-induced xerostomia in a multi-institutional setting and to assess severity of xerostomia. METHODS AND MATERIALS: Eligible patients had surgery for primary, neck dissection, and SGT, followed by XRT, during which the transferred salivary gland was shielded. Intensity modulated radiation therapy, amifostine, and pilocarpine were not allowed, but postoperative chemotherapy was allowed. Each operation was reviewed by 2 reviewers and radiation by 1 reviewer. If 13 or more (of 43) were "not per protocol," then the technique would be considered not reproducible as per study design. The secondary endpoint was the rate of acute xerostomia, grade 2 or higher, and a rate of ≤ 51% was acceptable. RESULTS: Forty-four of the total 49 patients were analyzable: male (81.8%), oropharynx (63.6%), stage IV (61.4%), median age 56.5 years. SGT was "per protocol" or within acceptable variation in 34 patients (77.3%) and XRT in 79.5%. Nine patients (20.9%) developed grade 2 acute xerostomia; 2 had grade 0-1 xerostomia (4.7%) but started on amifostine/pilocarpine. Treatment for these 11 patients (25.6%) was considered a failure for the xerostomia endpoint. Thirteen patients died; median follow-up for 31 surviving patients was 2.9 years. Two-year overall and disease-free survival rates were 76.4% and 71.7%, respectively. CONCLUSIONS: The technique of submandibular SGT is reproducible in a multicenter setting. Seventy-four percent of patients were prevented from XRT-induced acute xerostomia.
Authors: Jens Buentzel; Oliver Micke; Irenaus A Adamietz; Alain Monnier; Michael Glatzel; Alexander de Vries Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-21 Impact factor: 7.038
Authors: Siavash Jabbari; Hyungjin M Kim; Mary Feng; Alexander Lin; Christina Tsien; Mohamed Elshaikh; Jeffrey E Terrel; Carol Murdoch-Kinch; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2005-11-01 Impact factor: 7.038
Authors: D M Brizel; T H Wasserman; M Henke; V Strnad; V Rudat; A Monnier; F Eschwege; J Zhang; L Russell; W Oster; R Sauer Journal: J Clin Oncol Date: 2000-10-01 Impact factor: 44.544
Authors: J W Rieke; M D Hafermann; J T Johnson; F G LeVeque; R Iwamoto; B W Steiger; C Muscoplat; S C Gallagher Journal: Int J Radiat Oncol Biol Phys Date: 1995-02-01 Impact factor: 7.038
Authors: Naresh Jha; Hadi Seikaly; Jeffrey Harris; David Williams; Khalil Sultanem; Michael Hier; Sunita Ghosh; Martin Black; James Butler; Donna Sutherland; Paul Kerr; Pam Barnaby Journal: Head Neck Date: 2009-02 Impact factor: 3.147
Authors: Marije R Vergeer; Patricia A H Doornaert; Derek H F Rietveld; C René Leemans; Ben J Slotman; Johannes A Langendijk Journal: Int J Radiat Oncol Biol Phys Date: 2008-12-26 Impact factor: 7.038
Authors: Stephanie L Pugh; Gwen Wyatt; Raimond K W Wong; Stephen M Sagar; Bevan Yueh; Anurag K Singh; Min Yao; Phuc Felix Nguyen-Tan; Sue S Yom; Francis S Cardinale; Khalil Sultanem; D Ian Hodson; Greg A Krempl; Ariel Chavez; Alexander M Yeh; Deborah W Bruner Journal: J Pain Symptom Manage Date: 2016-11-27 Impact factor: 3.612
Authors: Alexandra E Quimby; Debora Hogan; Diana Khalil; Matthew Hearn; Colette Nault; Stephanie Johnson-Obaseki Journal: Int J Otolaryngol Date: 2020-08-06